Lexicon Director Acquires 150,000 Shares as Company Secures Financing and Moves Pilavapadin to Phase 3
Director Raymond Debbane purchased 150,000 shares of Lexicon Pharmaceuticals (NASDAQ: LXRX) in two transactions on February 19-20, 2026. The buying occurred as the stock has risen 107% over the past year and follows a financing package of roughly $100 million. The FDA has cleared Lexicon's pilavapadin to advance to two Phase 3, placebo-controlled, …